Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-1530 in Advanced or Metastatic Solid Tumors
NCT06874335Phase 1Recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Mar 2025
- Primary completion
- Mar 2029
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GQ1011 in solid tumor (2 arms), sponsored by Biohaven Ltd. Primary endpoints: Maximum Tolerable Dose at 48 months, Minimally Reproducible Active Dose at 48 months and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
GQ1011
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06874335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06874335.